Celyad lead compound in development, CAR T NKR-2, is currently being investigated in a second phase I in several oncology indications, five solid cancers and two hematological malignancies.
This investigational therapy is based on a unique CAR T construct, with a multi-pronged mechanism of action, which is based on a receptor that can binds to ligands that are expressed in 80% of cancer, which makes CAR T NKR-2 applicable to both hematological and solid cancers.
Before clinical data are available, Celyad experts developed a White Paper that describes the technology and early clinical development of the CAR T NKR-2 platform and elucidates its fundamental differences with classical CAR-T technologies, which could reshape the frontiers of cell-based cancer immunotherapy.
Click here to access the fully referenced White paper
About Celyad
Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized cell based therapies. The Company utilizes its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T-Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, the CAR-T NKR-2, has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and feasibility of CAR-T NKR-2 cells in patients suffering from AML or MM. This Phase I study was successfully completed in September 2016. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and Boston, Massachusetts. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on NASDAQ Global Market, all under the ticker symbol CYAD. For more information about Celyad, please visit: www.celyad.com
